Stress Disorders, Post-Traumatic Clinical Trial
Official title:
Cerebral Structure and Function Before and After Pharmacological and Psychological Treatment for PTSD
This study, conducted at the University of Pennsylvania and at the National Institutes of
Health in Bethesda, Maryland, will examine deficits in brain structure and function in
people exposed to trauma who developed post-traumatic stress disorder (PTSD) to see if these
deficits change after treatment. It also will investigate whether there is a genetic
susceptibility to PTSD.
Candidates 18 years of age and older in the following categories will be included in this
study: 1) women who have PTSD of at least 1 year's duration following sexual or non-sexual
assault; 2) healthy women (controls) who were previously assaulted but did not develop PTSD;
and 3) healthy women (controls) who were never traumatized. Candidates will be screened with
a medical history and physical examination, psychiatric evaluation, electrocardiogram (EKG),
and routine blood and urine tests.
Women with PTSD will be assigned to receive either: 1) 12 weeks of cognitive behavioral
psychotherapy either immediately upon enrollment or after a 3-month waiting period; or 2) 10
weeks of drug treatment with paroxetine (Paxil® (Registered Trademark)). Patients will be
evaluated before and after treatment with the procedures outlined below. Control subjects
will undergo the same procedures, also with a 10- to 12-week interval between evaluations.
- Neuropsychological testing: Subjects will take paper and pencil and computer tests to
evaluate memory, learning, attention and concentration, vocabulary and naming.
- Magnetic resonance imaging (MRI): Subjects will have MRI scans of the brain to examine
brain structure and blood flow while they perform two tasks. In the first task, they
will be shown a series of faces and asked to press one button for a male face and
another button for a female face. In the second task they will hear loud noises and see
colored squares. During the scan, subjects lie on a bed that slides into a narrow
tunnel (the scanner). They will wear a headset to block the noise of the scanner and
through which they will receive instructions for the tasks. Heart rate and skin
conductance (sweating) will be measured during the scan to evaluate physiologic changes
in response to the tasks.
- Eyeblink air puff test: Subjects will hear tones and will have a light puff of air
delivered to the eye. Changes in heart rate, sweat, and eyeblink will be measured with
electrodes taped to the skin on two fingers, on each side of the rib cage, and under
one eye.
- Potential air puff delivery: This experiment has three parts. During each of the three
parts of this experiment, subjects will see colored lights and may or may not receive a
puff of air to the neck. Before each part they will be told that they will, will not,
or may receive an air puff to the neck. Each part will be repeated several times.
During the test, electrodes will be taped to the arms and chest to monitor skin
conductance and heart rate responses.
- Blood draw for genetic evaluation: Subjects' DNA will be examined to try to determine
if the risk of developing PTSD is inherited. The DNA will be examined for cortisol
receptor gene evaluation, to see if a form of this gene is found more often in patients
with PTSD than in healthy controls. The receptor for cortisol determines the activity
of the stress hormone cortisol, and genetic variations in the structure of this
receptor may be related to vulnerability to PTSD.
Patients taking paroxetine will be offered up to 3 months of additional drug therapy
following completion of the study and will be offered participation in other NIH studies for
evaluation and treatment of PTSD.
Status | Completed |
Enrollment | 95 |
Est. completion date | September 2005 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Men and women aged 18-65, suffering from PTSD, healthy trauma survivors and never traumatized healthy subjects. PTSD diagnosis will be determined using the structured clinical interview for DSM IV (SCID)(155). Capable of providing informed consent, obtained prior to any study procedures. Free of all psychotropic medication for at least 2 weeks, excluding short-term hypnotics. Patients who were treated with fluoxetine will only be included after a medication free period of at least 8 weeks. Good physical health, confirmed by a complete physical exam (including normal vital signs), electrocardiogram, neurological exam, and routine laboratory tests of blood and urine. However, if patients have participated in other research studies or have had blood work through their primary MD within the last 6 months, these results will be used instead of repeating blood draws for inclusion into the study. Right handed, as determined by a handedness questionnaire. EXCLUSION CRITERIA: Past head trauma involving loss of consciousness, or amnesia greater than 24 hours. This magnitude of head trauma could contribute to psychopathology and brain structure in a manner different than PTSD thereby confounding results. Substance abuse (alcohol or drugs) or dependence within 3 months prior to screening. The effect of abuse/dependence on phenomenology and biology could mask and exceed PTSD effect. All additional DSM IV Axis I comorbidity, excluding secondary diagnoses of major depressive disorder (MDD) or anxiety disorders (AD). Given the high comorbidity of these disorders in PTSD, and since excluding such patients would not provide the full spectrum of the disorder, only patients in whom axis I diagnoses of MDD and AD preceded onset of PTSD will be excluded. Mental retardation or another pervasive developmental disorder. Risk of homicide or suicide. When the trauma involves assault, a continuing intimate relationship with the perpetrator. Current or intended pregnancy. If a participant becomes pregnant during the course of the study, her data will be removed from the analyses. Subjects who are doing well on medication. Although we will only recruit non-medicated patients, the decision to stop medication will be taken purely on clinical grounds. No subject will be taken off medication solely to participate in the study. Deafness will NOT exclude patients or healthy controls from participation. Accomodations and protocol adjustments (e.g., abbreviation of neuropsychological battery to eliminate tests which would be subjected to known or expected normalization violations) will be made as necessary for this population. |
N/A
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Mental Health (NIMH) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Mental Health (NIMH) |
United States,
Baxter LR Jr, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng HK, Munford P, et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992 Sep;49(9):681-9. — View Citation
Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR Jr. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001 Jul;58(7):631-40. — View Citation
Martin SD, Martin E, Rai SS, Richardson MA, Royall R. Brain blood flow changes in depressed patients treated with interpersonal psychotherapy or venlafaxine hydrochloride: preliminary findings. Arch Gen Psychiatry. 2001 Jul;58(7):641-8. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05620381 -
Health and Sleep Assessment After the Strasbourg Attacks of December 11, 2018
|
||
Completed |
NCT02856412 -
Improving Mind/Body Health and Functioning With Integrative Exercise
|
N/A | |
Recruiting |
NCT05400200 -
PTSD and Self-regulation: Coping, Emotional Regulation and Cognitive Control and Their Relationships to Symptom Management
|
N/A | |
Not yet recruiting |
NCT06088303 -
Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication
|
N/A | |
Not yet recruiting |
NCT03652922 -
Propranolol Reactivation Mismatch (PRM) Treatment for PTSD
|
Phase 4 | |
Completed |
NCT02875912 -
Prospective Evaluation of Family Care Rituals in the ICU
|
N/A | |
Completed |
NCT01589575 -
Anxiety and Depression in Relatives of Critically Ill Patients: Spouses Versus Other Close Relatives
|
N/A | |
Completed |
NCT00990106 -
Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT01291368 -
Sedation Influence on Delirium and Post-traumatic Stress-disorder as a Result of Hospitalization in Intensive Care
|
N/A | |
Active, not recruiting |
NCT00657787 -
Development of a Post-Traumatic Stress Disorder (PTSD) Population Registry for Veterans
|
||
Completed |
NCT01365247 -
Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00835627 -
Treatment Trial for Psychogenic Nonepileptic Seizures
|
Phase 4 | |
Completed |
NCT00880152 -
Mindfulness Based Stress Reduction for Posttraumatic Stress Disorder: A Pilot Study
|
N/A | |
Completed |
NCT00419029 -
Motivational Interviewing to Engage Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) Veterans in Mental Health Treatment
|
N/A | |
Completed |
NCT00514956 -
Effect of Emotional Freedom Technique and Diaphragmatic Breathing on Post Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
Completed |
NCT00333710 -
Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD
|
N/A | |
Completed |
NCT01120847 -
Post Traumatic Stress Disorder (PTSD), Sleep Disordered Breathing And Genetics: Effects On Cognition
|
||
Completed |
NCT00055354 -
Acupuncture for the Treatment of Post-Traumatic Stress Disorder (PTSD)
|
N/A | |
Completed |
NCT00186212 -
Alternative Support for Rural and Isolated Women in an HMO
|
Phase 3 | |
Completed |
NCT00000383 -
Treatment of Post-Traumatic Stress Disorder (PTSD) in Sexually Abused Children
|
N/A |